Neuronal degeneration inhibitors
By screening out small molecule compounds that inhibit RNA clusters and DPR generation, the problem of neurodegeneration in the prior art that fails to effectively inhibit motor neuronal diseases and dementia is solved, and agents are provided for preventing or treating these diseases. , effective treatment of diseases caused by abnormal amplification of the G4C2 repeat sequence of the C9orf72 gene was achieved.
Patent Information
- Application Number
- CN202180024013.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-27
- Filing Date
- 2021-03-26
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-03-26
AI Technical Summary
The prior art has failed to effectively inhibit the generation of RNA clusters and DPR caused by abnormal amplification of the G4C2 repeat sequence of the C9orf72 gene, resulting in neurodegeneration of motor neuronal diseases and dementia.
A neuronal degeneration inhibitor was developed, containing specific small molecule compounds, and differentiated motor neurons were induced by expression of Lhx3, Ngn2 and Isl1 genes, and seven compounds were screened for excellent inhibitory effects on RNA clusters and DPR generation.
These compounds are able to effectively inhibit the generation of RNA clusters and DPRs, providing agents for the prevention or treatment of motor neuronal diseases and dementia, showing significant in neurodegenerative diseases involving abnormal amplification of hexanucleotide repeats. Treatment effect.
Smart Images

Figure CN115335058B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a medicament (drug, pharmaceutical composition) comprising a compound for treating motor neuron disease or dementia. Background Art
[0002] Eukaryotic genomes contain various repetitive sequences, and recently, the hexanucleotide repetitive sequence "GGGGCC" (hereinafter also referred to as G4C2 repeat) located in the untranslated region of the C9orf72 gene has attracted attention as a link between amyotrophic lateral sclerosis (hereinafter also referred to as "ALS") and frontotemporal dementia (hereinafter also referred to as "FTD").
[0003] ALS is a typical motor neuron disease characterized by selective degeneration of upper motor neurons and lower motor neurons, of which approximately 10% of patients are sporadic and approximately 90% of patients are familial. So far, studies based on gene mutations found in familial patients have been widely conducted, and recently, abnormal expansion of the G4C2 repeat sequence of the C9orf72 gene has been identified as the most commonly observed gene abnormality in familial and sporadic ALS patients. On the other hand, FTD is characterized by degeneration of the frontal and temporal lobes of the brain and is the second most common disease in dementia patients under the age of 65, and it has been reported that the most commonly observed gene abnormality in FTD is also abnormal expansion of the G4C2 repeat sequence of the C9orf72 gene (Non-Patent Documents 1 and 2).
[0004] It is known that RNA transcribed from the C9orf72 gene having an abnormally expanded G4C2 repeat sequence is easily aggregated and encapsulates nuclear proteins to generate nuclear aggregates (hereinafter referred to as RNA clusters (RNA foci)) (Non-patent Documents 1 and 2). It is also known that the above RNA is translated into dipeptide repeat proteins (hereinafter referred to as DPRs) by repeat-related non-ATG translation (hereinafter referred to as RAN translation), and that DPRs generate intracellular inclusions (Non-patent Documents 3, 4, and 5). RNA clusters and DPRs are considered to be the main causes of neurodegeneration in these diseases due to their cytotoxicity (Non-patent Document 6), and it is believed that effectively inhibiting their generation can prevent the onset of these diseases or effectively inhibit the pathological progression after the onset.
[0005] So far, various model systems have been used to search for genes that can inhibit the generation of RNA clusters and / or DPRs. For example, by screening using a fruit fly model that expresses abnormally expanded G4C2 repeat sequences in the compound eye, FUS (the gene responsible for ALS6) was identified as a gene whose overexpression inhibits RNA translation and compound eye neurodegeneration (Patent Document 1). In addition, antisense oligonucleotides for the C9orf72 gene have also been developed and reported to inhibit the generation of RNA clusters and effectively inhibit neuronal death (e.g., Non-Patent Document 7).
[0006] However, small molecule compounds that can effectively inhibit the generation of RNA clusters and / or DPRs caused by G4C2 repeats have not been reported.
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: JP 2018-193309
[0010] Non-patent literature
[0011] Non-patent document 1: DeJesus-Hernandez, M. et al., Neuron 72, 245-56 (2011)
[0012] Non-patent document 2: Renton, AE et al., Neuron 72, 257-68 (2011)
[0013] Non-patent document 3: Ash, PE et al., Neuron 77, 639-46 (2013)
[0014] Non-patent document 4: Mori, K. et al., Science 339, 1335-8 (2013)
[0015] Non-patent document 5: Zu, T. et al., Proc Natl Acad Sci USA 110, E4968-77 (2013)
[0016] Non-patent document 6: J. Chew et al., Science, 348, 1151-1154 (2015)
[0017] Non-patent document 7: D. Sareen et al., Sci. Transl. Med., 5, 208ra149, doi: 10.1126 / scitranslmed.3007529 (2013) Summary of the invention
[0018] Problems to be solved by the present invention
[0019] The present invention aims to find compounds that can effectively inhibit the generation of RNA clusters and DPRs, which are considered to be the cause of neurodegeneration in motor neuron diseases and dementia represented by FTD, and to provide agents (drugs, pharmaceutical compositions) that can be used for the prevention or treatment of the above diseases.
[0020] Means of solving the problem
[0021] In order to solve the above problems, the present inventors have conducted extensive research and found for the first time that the motor neurons induced to differentiate by overexpression of Lhx3, Ngn2 and Isl1 genes of iPS cells derived from ALS patients with abnormally amplified G4C2 repeats spontaneously generate RNA clusters and DPRs, thereby leading to neurodegeneration. The present inventors have developed a method for inducing differentiation by expressing the three genes as a method capable of inducing differentiation into motor neurons with high synchronization in a short time (WO 2014 / 148646, and K. Imamura et al., Science Translational Medicine 2017, 9, eaaf3962).
[0022] Then, the present inventors have screened small molecule compounds using the above-mentioned motor neurons, and found that seven compounds have excellent inhibitory effects on the generation of RNA clusters and DPRs, that is, they can be agents for the prevention or treatment of motor neuron diseases and / or dementia caused by abnormal expansion of repetitive sequences, thereby completing the present invention.
[0023] Therefore, the present invention provides the following.
[0024] [1] A neuronal degeneration inhibitor (hereinafter also referred to as "the agent of the present invention") comprising a compound represented by formula (I)
[0025]
[0026] in
[0027] R 1 is a group represented by formula (a-1) or (a-2)
[0028]
[0029] in
[0030] R 11 and R 12 are independently a hydrogen atom or a C 1-6 alkyl,
[0031] R 13It is a hydrogen atom, a cyano group, a C 1-6 Alkyl-carbonyl or C 1-6 an alkoxy-carbonyl group, and
[0032] R 14 It is C 1-6 Alkyl, C 3-8 Cycloalkyl or C 6-14 Aryl,
[0033] R 2 is a group represented by formula (b-1) to (b-3)
[0034]
[0035] in
[0036] R 21 It is C 1-6 alkyl, C 6-14 Aryl or C optionally substituted by one or more halogen atoms 7-16 Aralkyl,
[0037] R 22 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C 1-6 Alkoxy, and
[0038] n is 0, 1, or 2,
[0039] R 3 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C 1-6 Alkoxy,
[0040] m is 0, 1, or 2, and
[0041] L is C 1-3 Alkylene,
[0042] or a salt thereof.
[0043] [2] The neuron degeneration inhibitor according to [1] above, wherein
[0044] R 11 and R 12 Both are hydrogen atoms,
[0045] R 13 is a hydrogen atom or C 1-6 Alkoxy-carbonyl,
[0046] R 14 It is C 1-6 alkyl,
[0047] R 21 It is C1-6 alkyl or C optionally substituted by one or more halogen atoms 7-16 Aralkyl,
[0048] R 22 is a halogen atom,
[0049] n is 0 or 1,
[0050] m is 0, and
[0051] L is a methylene group.
[0052] [3] The neuronal degeneration inhibitor according to the above-mentioned [1], wherein the compound represented by formula (I) or a salt thereof is selected from
[0053] (1) 4-(4-fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine,
[0054] (2) 1-(3-{[4-(2-methoxyphenyl)-1,3,5-triazine-2-yl]amino}phenyl)methanesulfonamide,
[0055] (3) 1-(3-{[4-(4-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide,
[0056] (4) 1-[3-({4-[2-(benzyloxy)phenyl]-1,3,5-triazin-2-yl}amino)phenyl]methanesulfonamide,
[0057] (5) 4-{2-[(3,4-dichlorophenyl)methoxy]phenyl}-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine,
[0058] (6) {[(3-{[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate,
[0059] (7) {[(3-{[4-(2,3-dihydro-1-benzofuran-7-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate,
[0060] And its salt.
[0061] [4] The neuron degeneration inhibitor according to any one of [1] to [3] above, which is used as an agent for preventing or treating motor neuron disease or dementia.
[0062] [5] The neuronal degeneration inhibitor according to the above-mentioned [4], wherein the motor neuron disease or dementia is a motor neuron disease or dementia involving abnormal expansion of a hexanucleotide repeat sequence.
[0063] [6] The neuron degeneration inhibitor according to the above-mentioned [4] or [5], wherein the motor neuron disease is amyotrophic lateral sclerosis.
[0064] [7] The neuronal degeneration inhibitor according to the above-mentioned [4] or [5], wherein the dementia is frontotemporal dementia.
[0065] [8] A method for inhibiting neuronal degeneration in a mammal, comprising administering to the mammal an effective amount of a compound or salt as defined in any one of [1] to [3] above.
[0066] [9] A method for preventing or treating a neurodegenerative disease in a mammal, comprising administering to the mammal an effective amount of a compound or salt as defined in any one of [1] to [3] above.
[0067]
[10] A compound or salt as defined in any one of [1] to [3] above, for use in preventing or treating a neurodegenerative disease.
[0068]
[11] Use of a compound or salt as defined in any one of [1] to [3] above for the manufacture of a medicament for preventing or treating a neurodegenerative disease.
[0069] Effects of the Invention
[0070] According to the present invention, there can be provided an agent which has an excellent inhibitory effect on the generation of RNA clusters and DPR in neurodegenerative diseases involving abnormal expansion of the G4C2 repeat sequence of the C9orf72 gene and can be used for preventing or treating the above diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] [ Figure 1 ]
[0072] Figure 1 Fluorescence microscopy images of RNA clusters visualized using fluorescent probes in motor neurons differentiated from ALS7(C9orf72) cells. DETAILED DESCRIPTION
[0073] The present invention is explained in detail below.
[0074] The present invention provides a neuronal degeneration inhibitor comprising a compound represented by the following formula (I) or a salt thereof (hereinafter also referred to as "compound (I)") as an active ingredient.
[0075]
[0076] in
[0077] R 1 is a group represented by formula (a-1) or (a-2)
[0078]
[0079] in
[0080] R 11 and R 12 are independently a hydrogen atom or a C 1-6 alkyl,
[0081] R 13 It is a hydrogen atom, a cyano group, a C 1-6 Alkyl-carbonyl or C 1-6 an alkoxy-carbonyl group, and
[0082] R 14 It is C 1-6 Alkyl, C 3-8 Cycloalkyl or C 6-14 Aryl,
[0083] R 2 is a group represented by formula (b-1) to (b-3)
[0084]
[0085] in
[0086] R 21 It is C 1-6 alkyl, C 6-14 Aryl or C optionally substituted by one or more halogen atoms 7-16 Aralkyl,
[0087] R 22 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C 1-6 Alkoxy, and
[0088] n is 0, 1, or 2,
[0089] R 3 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C 1-6 Alkoxy,
[0090] m is 0, 1, or 2, and
[0091] L is C 1-3 Alkylene.
[0092] The definition of each substituent used as used herein is explained in detail below. Unless otherwise stated, each substituent has the following definition.
[0093] As used herein, examples of the "halogen atom" include fluorine, chlorine, bromine and iodine.
[0094] As used herein, “C 1-6 Examples of the "alkyl" group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl.
[0095] As used herein, “C 3-8 Examples of "cycloalkyl" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl and adamantyl.
[0096] As used herein, “C 6-14 Examples of the "aryl group" include phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl and 9-anthryl.
[0097] As used herein, “C 7-16 Examples of "aralkyl" include benzyl, phenethyl, naphthylmethyl and phenylpropyl.
[0098] As used herein, “C 1-6 Examples of the "alkoxy" group include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy.
[0099] As used herein, “C 1-6 Examples of "alkyl-carbonyl" include acetyl, propionyl, butyryl, 2-methylpropionyl, valeryl, 3-methylbutyryl, 2-methylbutyryl, 2,2-dimethylpropionyl, hexanoyl and heptanoyl.
[0100] As used herein, “C 1-6 Examples of the "alkoxy-carbonyl group" include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl.
[0101] As used herein, “C 1-3Examples of "alkylene" include -CH2-, -(CH2)2-, -(CH2)3-, -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -C(CH3)2- and -CH(C2H5)-.
[0102] The definition of each symbol in formula (I) is explained in detail below.
[0103] R 1 is a group represented by formula (a-1) or (a-2)
[0104]
[0105] R 11 and R 12 are independently a hydrogen atom or a C 1-6 Alkyl, R 13 It is a hydrogen atom, a cyano group, a C 1-6 Alkyl-carbonyl or C 1-6 Alkoxy-carbonyl, and R 14 It is C 1-6 Alkyl, C 3-8 Cycloalkyl or C 6-14 Aryl.
[0106] R 11 and R 12 Both are preferably hydrogen atoms.
[0107] R 13 Preferably, it is a hydrogen atom or a C 1-6 The alkoxy-carbonyl group (eg ethoxycarbonyl group) is particularly preferably a hydrogen atom.
[0108] R 14 Preferably C 1-6 An alkyl group (such as a methyl group), particularly preferably a methyl group.
[0109] R 1 Preferred is a group represented by formula (a-2).
[0110] R 2 is a group represented by formula (b-1) to (b-3)
[0111]
[0112] R 21 It is C 1-6 alkyl, C 6-14 Aryl or C optionally substituted by one or more halogen atoms 7-16 Aralkyl, R 22 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C1-6 alkoxy, and n is 0, 1 or 2.
[0113] R 21 Preferably C 1-6 an alkyl group (e.g., a methyl group) or a C 7-16 Arylalkyl (e.g. benzyl), more preferably C 1-6 Alkyl group (eg methyl group), particularly preferably methyl group.
[0114] R 22 Preferred is a halogen atom (eg, a fluorine atom, a chlorine atom), and particularly preferred is a fluorine atom.
[0115] n is preferably 0 or 1, particularly preferably 1.
[0116] R 2 Preferred is a group represented by formula (b-1).
[0117] R 3 are independently a halogen atom, a cyano group, a C 1-6 Alkyl or C 1-6 Alkoxy.
[0118] m is 0, 1 or 2.
[0119] m is preferably 0.
[0120] L is C 1-3 Alkylene.
[0121] L is preferably methylene.
[0122] Preferred embodiments of compound (I) include the following compounds.
[0123] Compound (I) wherein
[0124] R 1 is a group represented by formula (a-1) or (a-2),
[0125] R 11 and R 12 Both are hydrogen atoms,
[0126] R 13 is a hydrogen atom or C 1-6 Alkoxy-carbonyl (eg ethoxycarbonyl),
[0127] R 14 It is C 1-6 Alkyl (e.g. methyl),
[0128] R 2 is a group represented by formula (b-1) to (b-3),
[0129] R 21 It is C 1-6 an alkyl group (e.g., a methyl group) or a C 7-16 Aralkyl (e.g. benzyl),
[0130] R 22 is a halogen atom (e.g., a fluorine atom, a chlorine atom),
[0131] n is 0 or 1,
[0132] m is 0, and
[0133] L is a methylene group.
[0134] Specific examples of compound (I) include the following compounds.
[0135] (1) 4-(4-fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine (Compound No. 1),
[0136] (2) 1-(3-{[4-(2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide (Compound No. 2),
[0137] (3) 1-(3-{[4-(4-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide (Compound No. 3),
[0138] (4) 1-[3-({4-[2-(benzyloxy)phenyl]-1,3,5-triazin-2-yl}amino)phenyl]methanesulfonamide (Compound Nos. 4a, 4b),
[0139] (5) 4-{2-[(3,4-dichlorophenyl)methoxy]phenyl}-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine (Compound No. 5),
[0140] (6) {[(3-{[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate (Compound No. 6),
[0141] (7) {[(3-{[4-(2,3-dihydro-1-benzofuran-7-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate (Compound No. 7),
[0142] And its salt.
[0143] When compound (I) is a salt, it is preferably a pharmaceutically acceptable salt. Examples of such salts include salts formed with inorganic bases, salts formed with organic bases, salts formed with inorganic acids, salts formed with organic acids, salts formed with basic amino acids, and salts formed with acidic amino acids.
[0144] Preferable examples of the salt with an inorganic base include alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt and the like; aluminum salts; and ammonium salts.
[0145] Preferred examples of the salt with an organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, tromethamine [tris(hydroxymethyl)methylamine], tert-butylamine, cyclohexylamine, benzylamine, dicyclohexylamine and N,N-dibenzylethylenediamine.
[0146] Preferred examples of the salt with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid.
[0147] Preferred examples of the salt with an organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
[0148] Preferable examples of the salt with a basic amino acid include salts with arginine, lysine and ornithine.
[0149] Preferred examples of the salt with an acidic amino acid include salts with aspartic acid and glutamic acid.
[0150] When compound (I) is obtained as a free form, it can be converted into a target salt according to a method known per se. When compound (I) is obtained as a salt, it can be converted into a target free form or other salt according to a method known per se.
[0151] As used herein, the term "neuronal degeneration" refers to any one or more abnormal occurrences of neurite atrophy, neurite breakage, neurite disappearance, cell body atrophy, cell body fragmentation, and cell body disappearance. Typically, neuronal degeneration can be detected and evaluated using cell death (in fact, as the opposite of the number of surviving neurons) as an indicator.
[0152] In addition, for neurodegeneration caused by abnormal expansion of a repetitive sequence having six (or three) nucleotide units, neurodegeneration can be detected and evaluated using an RNA cluster composed of RNA transcribed from the repetitive sequence or a DPR generated by RNA translation of the RNA as an indicator. Both RNA clusters and DPRs can be detected and quantified by well-known conventional methods.
[0153] For RNA clusters, for example, using oligonucleotides containing sequences complementary to the repetitive sequences (preferably labeled with fluorescence or the like) as probes, neurons are analyzed by the FISH (fluorescence in situ hybridization) method, and RNA clusters can be detected as fluorescent signal points (e.g., points with a diameter of 0.60 μm or more) present in the nucleus of neurons. The level of RNA cluster generation can be quantitatively evaluated by measuring the number of points per neuron or per unit area (e.g., observation field area, nuclear staining area in observation field, etc.).
[0154] For example, DPRs can be detected and quantified by analyzing neuron-derived lysates or extracts using antibodies against DPRs that may be generated from hexa(or tri)nucleotide repeats by well-known and conventional immunotechniques (e.g., ELISA methods). Alternatively, DPRs can be detected and quantified as antibody-positive spots by immunostaining neurons using the above antibodies.
[0155] In one embodiment, using motor neurons derived from iPS cells of ALS patients, the cell degeneration inhibition rate of motor neurons by a certain compound (test compound) can be calculated using the following formula.
[0156] Motor neuron degeneration inhibitory activity of the test compound = ((XC) / (TC)) x 100
[0157] X: the number of motor neurons in the test compound group on day y after the start of culture,
[0158] C: The number of motor neurons in the DMSO group on day y after the start of culture.
[0159] T: Number of motor neurons x days after the start of culture
[0160] Here, x is selected from any day before spontaneous cell death occurs in the subject, and y is selected from any day during which spontaneous cell death occurs in the subject.
[0161] Since compound (I) has an excellent inhibitory effect on the generation of RNA clusters and DPRs caused by abnormal amplification of G4C2 repeat sequences, the medicament of the present invention can be suitably used as a medicament for preventing or treating neurodegenerative diseases involving abnormal amplification of repeat sequences. In addition, since it is believed that there is a common mechanism of non-sequence dependence in the process of generating RNA clusters and DPRs from hexa (or tri) nucleotide repeat sequences, it is expected that the medicament of the present invention is used as a medicament for preventing or treating all neurodegenerative diseases involving abnormal amplification of hexa (or tri) nucleotides. The neurodegenerative diseases include motor neuron disease and dementia.
[0162] Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar palsy, spinal muscular atrophy, Parkinson's disease, multiple system atrophy, Huntington's disease, spinocerebellar degeneration, myotonic dystrophy, fragile x syndrome-related diseases, oculopharyngeal myopathy, Fuchs' corneal endothelial dystrophy, spherotomy muscular atrophy, etc. As used herein, these diseases are sometimes referred to as "motor neuron diseases." Among these diseases, amyotrophic lateral sclerosis, spherotomy muscular atrophy, myotonic dystrophy, Parkinson's disease, Huntington's disease, fragile x syndrome-related diseases, and spinal muscular atrophy are particularly preferably exemplified as target motor neuron diseases of the medicament according to the present invention.
[0163] Examples of dementia include frontotemporal dementia (FTD), Lewy body dementia, etc., and FTD is a particularly suitable target dementia disease.
[0164] The agent for the prevention or treatment can be used for the above-mentioned diseases whether they are sporadic or familial.
[0165] The agent for the prevention or treatment can be used as an agent for preventing or treating the above-mentioned diseases in mammals (eg, mice, rats, hamsters, rabbits, cats, dogs, cattle, sheep, monkeys, humans, etc.).
[0166] The agent of the present invention may contain one species of compound (I), or may contain two or more species of compound (I) in combination.
[0167] Compound (I) has better in vivo kinetics (e.g., plasma drug half-life, brain transferability, metabolic stability), and shows low toxicity (e.g., better as a drug in terms of acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interactions, carcinogenicity, etc.). Compound (I) is directly used as a medicament or a pharmaceutical composition mixed with a pharmaceutically acceptable carrier, etc., to be safely administered orally or parenterally to mammals (e.g., humans, monkeys, cattle, horses, pigs, mice, rats, hamsters, rabbits, cats, dogs, sheep, and goats). Examples of "parenteral" include intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, instillation, intracerebral, rectal, intravaginal, intraperitoneal, and intratumoral administration, administration near a tumor, etc., and direct administration to a lesion.
[0168] Although the dosage of compound (I) varies depending on the administration route, symptoms, etc., for example, when compound (I) is orally administered to a patient (adult, body weight 40-80 kg, for example, 60 kg) with amyotrophic lateral sclerosis, the dosage is, for example, 0.001-1000 mg / kg body weight / day, preferably 0.01-100 mg / kg body weight / day, more preferably 0.1-10 mg / kg body weight / day. This amount can be administered in 1 to 3 portions per day.
[0169] The medicament of the present invention can use compound (I) alone or compound (I) as a pharmaceutical composition containing compound (I) and a pharmaceutically acceptable carrier according to a method known per se as a method for producing a pharmaceutical preparation (e.g., a method described in the Japanese Pharmacopoeia, etc.). The medicament of the present invention (medicine, pharmaceutical composition) can be safely administered orally or parenterally (e.g., intravenously, intramuscularly, subcutaneously, intraorganically, intranasally, intradermally, by instillation, intracerebrally, intrarectally, intravaginally, intraperitoneally, and to a lesion) in the form of, for example, tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules, microcapsules), lozenges, syrups, liquids, emulsions. , suspensions, controlled release preparations (e.g., immediate release preparations, sustained release preparations, sustained release microcapsules), aerosols, films (e.g., orally disintegrating films, oral mucosal adhesive films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), drip injections, transdermal absorption preparations, ointments, lotions, viscous preparations, suppositories (e.g., rectal suppositories, vaginal suppositories), granules, nasal preparations, pulmonary preparations (inhalants), eye drops, etc.
[0170] As the aforementioned "pharmaceutically acceptable carrier", various organic or inorganic carriers conventionally used as preparation materials (starting materials) can be used. For example, excipients, lubricants, binders, disintegrants, etc. are used for solid preparations, and solvents, solubilizers, suspending agents, isotonic agents, buffers, soothing agents, etc. are used for liquid preparations. If necessary, preparation additives such as preservatives, antioxidants, colorants, sweeteners, etc. can also be used.
[0171] Examples of the excipient include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose and light anhydrous silicic acid.
[0172] Examples of lubricants include magnesium stearate, calcium stearate, talc and colloidal silicon dioxide.
[0173] Examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, starch, sucrose, gelatin, methyl cellulose and sodium carboxymethyl cellulose.
[0174] Examples of disintegrants include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl starch sodium and L-hydroxypropyl cellulose.
[0175] Examples of the solvent include water for injection, alcohol, propylene glycol, Macrogol, sesame oil, corn oil, and olive oil.
[0176] Examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate.
[0177] Examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate, etc.; and hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.
[0178] Examples of isotonic agents include glucose, D-sorbitol, sodium chloride, glycerol, and D-mannitol.
[0179] Examples of buffers include buffer solutions such as phosphate, acetate, carbonate, and citrate.
[0180] Examples of soothing agents include benzyl alcohol.
[0181] Examples of preservatives include parabens, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.
[0182] Examples of antioxidants include sulfites, ascorbic acid and alpha-tocopherol.
[0183] Although the pharmaceutical composition (formulation) varies depending on the dosage form, administration method, carrier and the like, it can be produced according to a conventional method by adding compound (I) in a proportion of generally 0.01% to 100% (w / w), preferably 0.1% to 95% (w / w) of the total preparation.
[0184] Compound (I) can be used as a medicament (drug, pharmaceutical composition) alone or in combination of two or more thereof. As used herein, unless otherwise specified, Compound (I) also includes a combination of plural kinds thereof.
[0185] Furthermore, compound (I) may be used in combination with other active ingredients (hereinafter referred to as concomitant drugs).
[0186] Examples of concomitant medications include the following. (benzodiazepine) (chlordiazepoxide, diazepam, potassium clorazepate, lorazepam, clonazepam, alprazolam, etc.), L-type calcium channel inhibitors (pregabalin, etc.), tricyclic or tetracyclic antidepressants (imipramine hydrochloride, amitriptyline hydrochloride, desipramine hydrochloride, clomipramine hydrochloride, etc.), selective serotonin reuptake inhibitors (fluvoxamine maleate, fluoxetine hydrochloride, citalopram hydrobromide, sertraline hydrochloride, paroxetine hydrochloride, etc.), hydrochloride), escitalopram oxalate, etc.), serotonin-norepinephrine reuptake inhibitors (venlafaxine hydrochloride, duloxetine hydrochloride, desvenlafaxine hydrochloride, etc.), norepinephrine reuptake inhibitors (reboxetine mesylate, etc.), norepinephrine-dopamine reuptake inhibitors (bupropion hydrochloride, etc.), mirtazapine, trazodone hydrochloride, nefazodone hydrochloride, bupropion hydrochloride, setiptiline maleate, 5-HT 1AAgonists (buspirone hydrochloride, tandospirone citrate, osemozotan hydrochloride, etc.), 5-HT3 antagonists (Cyamemazine, etc.), non-selective cardiac β inhibitors (propranolol hydrochloride, oxprenolol hydrochloride, etc.), histamine H1 antagonists (hydroxyzine hydrochloride, etc.), drugs for the treatment of schizophrenia (chlorpromazine, haloperidol, sulpiride, clozapine, trifluoperazine hydrochloride, fluphenazine hydrochloride, olanzapine, quetiapine fumarate fumarate), risperidone, aripiprazole, etc.), CRF antagonists, other antianxiety drugs (meprobamate, etc.), tachykinin antagonists (MK-869, saredutant, etc.), drugs acting on metabotropic glutamate receptors, CCK antagonists, β3 adrenergic antagonists (amibegron hydrochloride, etc.), GAT-1 inhibitors (tiagabine hydrochloride, etc.), N-type calcium channel inhibitors, carbonic anhydrase II inhibitors, NMDA glycine partial agonists, NMDA antagonists (memantine, etc.), peripheral benzodiazepines Receptor agonists, vasopressin antagonists, vasopressin V1b antagonists, vasopressin V1a antagonists, phosphodiesterase inhibitors, opioid antagonists, opioid agonists, uridine, nicotinic acid receptor agonists, thyroid hormones (T3, T4), TSH, TRH, MAO inhibitors (phenelzine sulfate, tranylcypromine sulfate, moclobemide, etc.), 5-HT 2A Antagonists, 5-HT 2AInverse agonists, COMT inhibitors (entacapone, etc.), drugs for treating bipolar disorder (lithium carbonate, sodium valproate, lamotrigine, riluzole, felbamate, etc.), cannabinoid CB1 antagonists (rimonabant, etc.), FAAH inhibitors, sodium channel inhibitors, anti-ADHD drugs (methylphenidate hydrochloride, methamphetamine hydrochloride, etc.) hydrochloride, etc.), drugs for alcoholism, drugs for autism, drugs for chronic fatigue syndrome, drugs for spasticity, drugs for fibromyalgia syndrome, drugs for headache, drugs for insomnia (etizolam, zopiclone, triazolam, zolpidem, ramelteon, indiplon, etc.), drugs for smoking cessation, drugs for myasthenia gravis, drugs for cerebral infarction, drugs for mania, drugs for excessive sleep, drugs for pain, drugs for dysthymia, drugs for autonomic ataxia, drugs for male and female sexual dysfunction, drugs for migraine, drugs for pathological gamblers, drugs for restless legs syndrome, drugs for substance addiction, drugs for alcohol-related syndrome, drugs for irritable bowel syndrome, drugs for Alzheimer's disease (donepezil, adderall drugs for treating Parkinson's disease (levodopa, carbidopa, benserazide, selegiline, zonisamide, entacapone, amantadine, talipexole, pramipexole, apomorphine, cabergoline, bromocriptine, istradefylline, trihexyphenidyl, promethazine, pergolide, etc.), drugs for treating Huntington's disease (chlorpromazine hydrochloride,hydrochloride, haloperidol, reserpine, etc.), drugs for Gaucher's disease (imiglucerase, taliglucerase alfa, velaglucerase alfa, eliglustat, miglustat, etc.), drugs for ALS (riluzole, etc., neurotrophic factors, etc.), drugs for multiple sclerosis (molecular targeted drugs, such as fingolimod, interferon β1b, natalizumab, etc.), anti-epileptic drugs (phenytoin, carbamazepine, phenobarbital, primidone, zonisamide, sodium valproate (sodium valproate), ethosuximide, diazepam, nitrazepam, clonazepam, clobazam, gabapentin, topiramate, lamotrigine, levetiracetam, stiripentol, rufinamide, etc.), drugs for the treatment of dyslipidemia such as cholesterol-lowering drugs (statin series (pravastatin sodium (pravastatin sodium), atorvastatin, simvastatin, rosuvastatin, etc.), fibrates (clofibrate, etc.), squalene synthetase inhibitors), drugs for treating abnormal behavior caused by dementia or drugs for suppressing wandering (sedatives, antianxiety drugs, etc.), apoptosis inhibitors, anti-obesity drugs, drugs for treating diabetes, drugs for treating hypertension, drugs for treating hypotension, drugs for treating rheumatism (DMARD), anticancer drugs, drugs for treating parathyroid gland (PTH ), calcium receptor antagonists, sex hormones or their derivatives (progesterone, estradiol, estradiol benzoate, etc.), neuron differentiation promoters, nerve regeneration promoters, nonsteroidal anti-inflammatory drugs (meloxicam, tenoxicam, indomethacin, ibuprofen, celecoxib, rofecoxib, aspirin, etc.), steroids (dexamethasone, cortisone acetate, etc.),acetate), anti-cytokine drugs (TNF inhibitors, MAP kinase inhibitors, etc.), antibody drugs, nucleic acids or nucleic acid derivatives, aptamer drugs, etc.
[0187] By combining compound (I) with a concomitant drug, a better effect can be achieved, such as
[0188] (1) the dosage can be reduced compared with single administration of compound (I) or concomitant drug,
[0189] (2) The drug to be combined with compound (I) can be selected according to the patient's condition (mild, severe, etc.),
[0190] (3) A longer treatment period can be set by selecting a concomitant drug with a different action and mechanism from compound (I),
[0191] (4) A sustained therapeutic effect can be designed by selecting a concomitant drug with a different action and mechanism from compound (I).
[0192] (5) A synergistic effect can be provided by the combined use of compound (I) and a concomitant drug, etc.
[0193] Hereinafter, the compound (I) and the concomitant drug used in combination are referred to as "the combination agent of the present invention".
[0194] When using the combination of the present invention, the administration time of compound (I) and concomitant drug is not limited, and compound (I) or its pharmaceutical composition and concomitant drug or its pharmaceutical composition can be administered to the subject at the same time, or can be administered at different times. The dosage of the concomitant drug can be determined according to the dosage used in clinical practice, and can be appropriately selected according to the subject, route of administration, disease, combination, etc.
[0195] The administration mode of the concomitant drug of the present invention is not particularly limited, and it is sufficient to combine compound (I) and the concomitant drug in the administration. Examples of such administration modes include the following methods:
[0196] (1) administering a single preparation obtained by simultaneously processing compound (I) and a concomitant drug, (2) administering two kinds of preparations of compound (I) and a concomitant drug produced separately simultaneously through the same administration route, (3) administering two kinds of preparations of compound (I) and a concomitant drug produced separately in a staggered manner through the same administration route, (4) administering two kinds of preparations of compound (I) and a concomitant drug produced separately simultaneously through different administration routes, (5) administering two kinds of preparations of compound (I) and a concomitant drug produced separately in a staggered manner (for example, administering in the order of compound (I) and the concomitant drug or in the reverse order) through different administration routes, etc.
[0197] The combination of the present invention exhibits low toxicity. For example, compound (I) or (and) the aforementioned concomitant drug can be combined with a pharmacologically acceptable carrier according to a known method to prepare a pharmaceutical composition, such as tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), liquids, injections, suppositories and sustained release agents. These compositions can be safely administered orally or non-orally (for example, topically, rectally, intravenously). Injection can be intravenous, intramuscular, subcutaneous or administered by intra-organ administration or directly administered to the lesion.
[0198] Examples of pharmacologically acceptable carriers that can be used to produce the combined pharmaceutical preparation of the present invention include those similar to the above-mentioned carriers.
[0199] The mixing ratio of compound (I) and concomitant drug in the combination drug of the present invention can be appropriately selected depending on the administration subject, administration route, disease and the like.
[0200] For example, the content of Compound (I) in the combination pharmaceutical of the present invention varies depending on the form of the preparation and is generally about 0.01 wt % to about 100 wt %, preferably about 0.1 wt % to about 50 wt %, further preferably about 0.5 wt % to about 20 wt % based on the preparation.
[0201] The content of the concomitant drug in the combination pharmaceutical of the present invention varies depending on the form of the preparation and is generally about 0.01 to about 100 wt %, preferably about 0.1 to about 50 wt %, further preferably about 0.5 to about 20 wt % based on the preparation.
[0202] Example
[0203] The present invention is explained in detail below by referring to Examples and Experimental Examples, which should not be construed as limitative, and the present invention can be varied within the scope of the present invention.
[0204] The test compounds used in the following experimental examples are as follows.
[0205] Table 1
[0206]
[0207] 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazin-2-amine (Compound No. 1) is described in Example 2 of WO 2012 / 160034.
[0208] 1-(3-{[4-(2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide (Compound No. 2) is described as Compound Bl in WO 2011 / 116951.
[0209] 1-(3-{[4-(4-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide (Compound No. 3) is described as Compound B6 in WO 2011 / 116951.
[0210] 1-[3-({4-[2-(benzyloxy)phenyl]-1,3,5-triazin-2-yl}amino)phenyl]methanesulfonamide (Compound No. 4b) and its trifluoroacetic acid salt (Compound No. 4a) are described as Compound B13 in WO 2011 / 116951.
[0211] 4-{2-[(3,4-dichlorophenyl)methoxy]phenyl}-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine (Compound No. 5) is described in Example 61 of WO 2012 / 160034.
[0212] {[(3-{[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate (Compound No. 6) is described in Example 37 of WO 2012 / 160034.
[0213] {[(3-{[4-(2,3-dihydro-1-benzofuran-7-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate (Compound No. 7) is described in Example 33 of WO 2012 / 160034.
[0214] Experimental Example 1
[0215] The effect of the compounds used in the present invention on RNA clusters was examined using the ALS7 (C9orf72) cell line described in K. Imamura et al., Science Translational Medicine 2017, 9, eaaf3962. The cell line is a stable cell line prepared by introducing tetracycline-induced Lhx3, Ngn2 and Isl1 genes into an iPS cell line established from a familial ALS patient with abnormal amplification of the G4C2 repeat sequence of the C9orf72 gene. Therefore, ALS7 (C9orf72) cells are ALS cell models that can be rapidly differentiated into motor neurons (within about 7 days) after tetracycline or its derivatives are added to the culture medium, and after differentiation, spontaneously continue to cell death (see the above document). In addition, the inventors have found that the generation of RNA clusters and DPRs occurs spontaneously before cell death.
[0216] ALS7 (C9orf72) cells were cultured on feeder cells (mitomycin-treated SNL cells) using iPS cell maintenance medium composed of primate ES cell medium (ReproCell, RCHEMD001A), 4 ng / ml hbFGF (Wako, 060-04543), 50 μg / ml G418 (Nacalai, 09380-86) and penicillin-streptomycin (Thermo Fisher Scientific, 15140-122).
[0217] The method for seeding ALS7 (C9orf72) cells on assay plates was as follows.
[0218] Artificial basement membrane (BD Falcon, D2650) was coated with DMEM / F-12 (1:1) (Thermo Fisher Scientific, 11330-057), N2 supplement (Thermo Fisher Scientific, 17502-048), penicillin-streptomycin (Thermo Fisher Scientific, 15140-122), 10 ng / ml recombinant human BDNF (PeproTech, 450-02), 10 ng / ml recombinant human GDNF (PeproTech, 450-10), 10 ng / ml recombinant human NT-3 (PeproTech, 450-03), 1 μM retinoic acid (Sigma, R2625), 1 μg / ml doxycycline (Clontech, 631311), 1 μM SAG (Enzo life sciences, ALX-270-426-M001) and 10 μM The assay medium composed of Y-27632 (Wako, 253-00513) was diluted 20-fold, and then a 384-well plate (CellCarrier-384Ultra, PerkinElmer, 6057300) was coated with the diluted solution.
[0219] ALS7 (C9orf72) cells were then suspended in assay medium and cultured at 1×10 4 Cells / well were seeded on Matrigel-coated assay plates.
[0220] The method for fluorescent staining of RNA clusters in motor neurons differentiated from ALS7(C9orf72) cells was as follows.
[0221] For ALS7 (C9orf72) cells seeded on the assay plate according to the method described in the previous section, assay medium without Y-27632 was added to the plate four days after seeding, and the cells were cultured. Seven days after seeding, assay medium containing the test compound at a predetermined concentration (retinoic acid, doxycycline, SAG, no Y-27632) was added to the plate by medium exchange, and one day after the addition of the test compound, PFA (Wako, 163-20145) was added to the plate to fix the cells. After washing with PBS (Wako, 045-29795) was repeated three times, ice-cold methanol (Wako, 131-01826) was added to the plate, and the plate was allowed to stand at room temperature for 10 minutes. The DNA probe [5'-(Cy3)-CCCCGGCCCCGGCCCCGGCCCCGG-3' (SEQ ID NO: 1), SIGMA genosys, custom synthesis] was denatured at 80°C for 75 s, prepared to 2 μg / μL in a hybridization buffer consisting of 50% formamide (Wako, 066-02301), 2xSSC (Nippon Gene, 319-90015), 50 mM sodium phosphate (TEKNOVA, P2070), 10% dextran sulfate (SIGMA, D8906-100G), 0.1 mg / mL yeast tRNA (INVITRON, 15401029) and RNase-free water (QIAGEN, 129112), and added to the plate, and the plate was allowed to stand at 37°C for 16 to 24 h to allow the probe to bind to the RNA clusters. A washing buffer consisting of 50% formamide, 1xSSC and RNase-free water was added to the plate, and the plate was allowed to stand at 37°C for 30 minutes, then washed with PBS. Hoechst (invitrogen, H3569) diluted 5000 times with PBS was added to the plate, and the plate was allowed to stand at room temperature for 20 minutes to stain the cell nuclei, then washed with PBS.
[0222] RNA clusters in the nucleus were detected by analyzing the above treated plates with a high content analyzer (measuring Cy3 fluorescence). The high content analyzer used was Opera phoenix from PerkinElmer. Figure 1 A typical image acquired via Opera is shown.
[0223] The method for detecting the activity of the test compounds is as follows.
[0224] As a negative control, cells (motor neurons induced to differentiate from ALS7 (C9orf72)) cultured in assay medium supplemented with DMSO (instead of the test compound) were used. Because cells were layered and nuclei overlapped each other in some cases, the nuclear staining area was used as an indicator of cell number. Variations in cell number were corrected by dividing the number of RNA clusters in the nucleus by the nuclear staining area.
[0225] The degree to which the test compound reduced the number of RNA clusters in the negative control was defined as the RNA cluster inhibitory activity of the test compound, which was calculated by the following formula.
[0226] Testing compounds for RNA clustering inhibition activity
[0227] =100-X / C×100
[0228] X: the number of RNA clusters per constant nuclear region in the test compound group,
[0229] C: Number of RNA clusters per constant nuclear region in the DMSO group
[0230] The activities at test compound concentrations of 1, 3 and 10 μmol / l are shown in Table 2 below.
[0231] [Table 2]
[0232]
[0233] As shown in Table 2, spontaneous RNA cluster generation in ALS7 (C9orf72) cell-derived motor neurons was effectively inhibited when treated with any of the compounds. In particular, Compound Nos. 1, 4a, 4b, and 5-7 inhibited RNA cluster generation by 40% or more in a wide concentration range of 1-10 μM.
[0234] Therefore, it is shown that the compounds according to the present invention can effectively inhibit the generation of RNA clusters caused by abnormal expansion of G4C2 repeat sequences.
[0235] Experimental Example 2
[0236] Next, the effects of the compounds used in the present invention on RAN translation were examined. In the DPRs generated by RAN translation, the poly-GP level was measured by an electrochemiluminescence system (Meso Scale Diagnostics).
[0237] ALS7 (C9orf72) cells were seeded on the assay plate by the same procedure as in Experimental Example 1. Four days after seeding, an assay medium without Y-27632 was added to the plate, and the cells were cultured until seven days after seeding, and an assay medium containing a test compound at a predetermined concentration (retinoic acid, doxycycline, SAG, no Y-27632) was added to the plate by medium exchange. Two days after the addition of the test compound, the medium was removed, and the cells were lysed in a urea buffer composed of 8 M urea (Wako, 219-00175), 4% CHAPS (Dojindo, 349-04722), and 30 mM Tris-HCl (pH 8.0, Nippon Gene, 312-90061). The cell lysate was added to a multi-array 384-well plate (Meso Scale Diagnostics, L21XB-4), and the plate was shaken at 700 rpm at room temperature with a plate shaker (Azwan, DM-301), and then the plate was allowed to stand overnight at 4° C. The cell lysate was removed, and a blocking buffer consisting of 5% blocking agent A (Meso Scale Diagnostics, R93AA-1) and 1×TBS-T {TBS (Bio-Rad, 170-6435) containing 0.05% Tween-20 (Bio-Rad, 170-6531)} was added to the plate, and the plate was shaken at 700 rpm at room temperature with a plate shaker for 1 h, and then washed three times with a washing buffer consisting of 0.05% Tween-20 and PBS (Wako, 162-18547). C9RANT antibody (Novus Biologicals, NBP2-25018) diluted 10,000 times with 1xTBS-T containing 1% blocking agent A was added to the plate, and the plate was shaken at 700 rpm for 2 h at 4 ° C with a plate shaker, and then the plate was allowed to stand overnight at 4 ° C. After washing three times with washing buffer, SULFO-TAG goat anti-rabbit antibody (Meso Scale Diagnostics, R32AB-1) diluted 500 times with 1xTBS-T containing 1% blocking agent A was added to the plate, and the plate was shaken at 700 rpm for 2 h at room temperature with a plate shaker. After washing three times with washing buffer, 2xMSD read buffer T (Meso Scale Diagnostics, R92TC-1) containing surfactant was added to the plate, and the signal derived from C9RANT antibody was measured by Meso SECTOR S600 (MesoScale Diagnostics).
[0238] The method for detecting the activity of the test compounds is as follows.
[0239] As negative control, cells cultured in assay medium supplemented with DMSO instead of test compound were used.
[0240] The extent to which the test compound reduced the poly-GP level in the negative control was defined as the RAN translation inhibitory activity of the test compound, which was calculated by the following formula.
[0241] Testing compounds for RAN translation inhibition activity
[0242] =100-X / C×100
[0243] X: Poly-GP level in the test compound group,
[0244] C: Poly-GP levels in the DMSO group
[0245] The activities at test compound concentrations of 1, 3 and 10 μmol / l are shown in Table 3 below.
[0246] [Table 3]
[0247]
[0248] As shown in Table 3, when treated with any of the compounds, poly-GP production in ALS7 (C9orf72) cell-derived motor neurons was effectively inhibited.
[0249] Therefore, it was shown that the compound according to the present invention can effectively inhibit the RAN translation caused by the abnormal expansion of the G4C2 repeat sequence.
[0250] Experimental Example 3
[0251] To examine the cytotoxicity of the test compounds, intracellular ATP levels were measured.
[0252] ALS7 (C9orf72) cells were seeded on the assay plate in the same procedure as in Experimental Example 1. Four days after seeding, an assay medium without Y-27632 was added to the plate, and the cells were cultured until seven days after seeding, and an assay medium containing a test compound at a predetermined concentration (retinoic acid, doxycycline, SAG, no Y-27632) was added to the plate by medium exchange. 24 h or 48 h after adding the test compound, the medium was removed, and the CellTiter-Glo luminescent cell viability assay (Promega, G7570) was performed.
[0253] The method for detecting the cytotoxicity of the test compounds is as follows.
[0254] As negative control, cells cultured in assay medium supplemented with DMSO instead of test compound were used.
[0255] The extent of the effect on the intracellular ATP level in the test compound-treated cells was defined as the ATP level of the test compound compared to the negative control, which was calculated by the following formula.
[0256] ATP level of test compound compared to negative control = X / C x 100
[0257] X: ATP level in the test compound group,
[0258] C: ATP level in DMSO group
[0259] When the intracellular ATP level was less than 0.5 times or greater than 1.5 times that in the negative control, it was judged as cytotoxic.The intracellular ATP levels at test compound concentrations of 1, 3 and 10 μmol / l are shown in Table 4 below.
[0260] [Table 4]
[0261]
[0262] As shown in Table 4, when treated with any of the compounds, the intracellular ATP level in ALS7 (C9orf72) cell-derived motor neurons ranged from 0.5 to 1.5 times that in the negative control. Even when each compound was treated for 48 hours, the level was within the above range. Therefore, it is considered that the cytotoxicity of the compounds according to the present invention is sufficiently low. In particular, for compounds 1, 6, and 7, even when treated for 48 hours in a concentration range of 1-10 μM, the intracellular ATP level was maintained at 80% or more of that in the negative control. Therefore, it is considered that the cytotoxicity is extremely low.
[0263] As is clear from these results, it is shown that the compound according to the present invention can effectively inhibit RNA clustering and RNA translation caused by abnormal expansion of G4C2 repeat sequences within a concentration range with sufficiently low cytotoxicity.
[0264] It can be expected that, similarly to Compound Nos. 1 to 7, the compounds of Reference Examples 1 to 30 shown in Table 5 below can also inhibit RNA clustering and RNA translation.
[0265] [Table 5-1]
[0266]
[0267] [Table 5-2]
[0268]
[0269] [Table 5-3]
[0270]
[0271] [Table 5-4]
[0272]
[0273] [Table 5-5]
[0274]
[0275] Formulation Examples
[0276] The pharmaceutical preparation containing the compound of the present invention as an active ingredient can be produced, for example, by the following formulation.
[0277] 1. Capsules
[0278]
[0279] The total amount of the above (1), (2) and (3) was blended and granulated with 5 mg of (4), and 5 mg of the remaining (4) was added. The entire mixture was sealed in a gelatin capsule.
[0280] 2. Tablets
[0281]
[0282] The total amount of the above (1), (2) and (3), 20 mg of (4) and 2.5 mg of (5) were blended and granulated, and 10 mg of the remaining (4) and 2.5 mg of the remaining (5) were added, and the mixture was compression-molded to obtain tablets.
[0283] Industrial Applicability
[0284] The compounds according to the present invention can effectively inhibit the generation of RNA clusters and the generation of DPRs translated by RAN in neurodegenerative diseases (e.g., ALS or FTD) caused by abnormal amplification of G4C2 repeat sequences, and can prevent or treat such diseases. Some neurodegenerative diseases are caused by abnormal amplification of repeat sequences composed of different six (or three) nucleotide sequences, and in any case, the generation of RNA clusters and DPRs is considered to be the main cytotoxicity leading to neurodegeneration. In addition, it has been suggested that there is a common mechanism of non-sequence dependence in the generation of RNA clusters and DPRs.
[0285] Therefore, it is expected that the compound according to the present invention can contribute as a pharmaceutical agent for preventing or treating not only neurodegenerative diseases caused by abnormal expansion of G4C2 repeat sequences but also all neurodegenerative diseases caused by abnormal expansion of nucleotide repeat sequences.
[0286] This application is based on patent application No. 2020-058414 filed in Japan on March 27, 2020, the contents of which are incorporated herein in their entirety.
Claims
1. Use of a compound represented by formula (I) or a salt thereof in the preparation of a medicament for treating amyotrophic lateral sclerosis or frontotemporal dementia caused by abnormal expansion of a G4C2 repeat sequence in R 1 is a group represented by formula (a-1) or (a-2) in R 11 and R 12 Both are hydrogen atoms, R 13 is a hydrogen atom or C 1-6 an alkoxy-carbonyl group, and R 14 It is C 1-6 alkyl, R 2 is a group represented by formula (b-1) to (b-3) in R 21 It is C 1-6 alkyl or C optionally substituted by one or more halogen atoms 7-16 Aralkyl, R 22 is a halogen atom, and n is 0 or 1, m is 0, and L is a methylene group.
2. The use according to claim 1, wherein in formula (I): R 1 is a group represented by formula (a-2) Each symbol is as defined in claim 1.
3. The use according to claim 1, wherein in formula (I): R 2 is a group represented by formula (b-1) Each symbol is as defined in claim 1.
4. The use according to claim 1, wherein in formula (I): R 11 and R 12 Both are hydrogen atoms, R 13 is a hydrogen atom or an ethoxycarbonyl group, R 14 It is methyl. R 21 is methyl or benzyl which is optionally substituted by one or more chlorine atoms, R 22 is a halogen atom, n is 0 or 1, m is 0, and L is a methylene group.
5. The use according to claim 1, wherein the compound represented by formula (I) or a salt thereof is selected from (1) 4-(4-fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine, (2) 1-(3-{[4-(2-methoxyphenyl)-1,3,5-triazine-2-yl]amino}phenyl)methanesulfonamide, (3) 1-(3-{[4-(4-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methanesulfonamide, (4) 1-[3-({4-[2-(benzyloxy)phenyl]-1,3,5-triazin-2-yl}amino)phenyl]methanesulfonamide, (5) 4-{2-[(3,4-dichlorophenyl)methoxy]phenyl}-N-{3-[(S-methylsulfonylimino)methyl]phenyl}-1,3,5-triazine-2-amine, (6) {[(3-{[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate, (7) {[(3-{[4-(2,3-dihydro-1-benzofuran-7-yl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](methyl)oxy-λ 6 -sulfinyl}ethyl carbamate, And its salt.
